R&D When is the superbug message going to bite? As existing antibiotics become less effective, we edge closer to a future where routine infections & minor injuries could once again become high risk.
News Roche takes new antibiotic into phase 3 for 'urgent threat' Roche is moving its antibiotic zosurabalpin into phase 3 for CRAB, potentially a big step forward in the fight against antimicrobial resistance.
R&D Growing threat of AMR: UN calls for urgent global action In response to the rise of AMR, world leaders recently convened at the United Nations General Assembly to forge a landmark commitment, setting ambitious targets and funding initiatives to c
R&D LSX 2024 - James Graham, Recce Pharma A lot of ink has been spilled about the anti-microbial resistance space and why it’s so hard to create a profitable company in it.
Market Access Overcoming AMR market failure: Three start-up stories Slowly but surely, the world’s antibiotics are becoming less effective as disease-causing bacteria evolve into drug-resistant “superbugs”.
R&D AI and the battle against AMR One of the largest threats facing public health is growing resistance to the world’s existing antibiotics.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.